# Bioinformatics Analysis of Peroxisomal Biogenesis Factor Proteins in Breast Malignancy for Introducing Potential Prognostic Biomarkers

## TL;DR

This study explores peroxisomal biogenesis factors in breast cancer to identify potential biomarkers for prognosis and treatment.

## Contribution

The study identifies specific PEX proteins and miRNAs correlated with breast cancer survival and progression.

## Key findings

- PEX6/7/10/13/16 are overexpressed in breast cancer tissues.
- High PEX2/3/12/19 expression correlates with better survival in breast cancer patients.
- has-miR-4318 and has-7106-3p are miRNAs significantly associated with PEX family expression.

## Abstract

Breast cancer (BC) is the most common type of malignant neoplasm and is the primary cause of mortality among women aged 45 to 55 years. Studies indicate that cancer displays irregular metabolic patterns in contrast to normal tissue. Furthermore, there is compelling evidence supporting the significant role of peroxisomes in the intricate metabolic processes of cancer. Peroxisomal biogenesis factors (PEXs), which are peroxisomal proteins, control activities such as the degradation and biogenesis of peroxisomes. Hence, the correlation between peroxisomal biogenesis factor expression and BC was explored, to introduce key proteins and potential biomarkers by analyzing.

This study utilized UALCAN, GenExMiner v4.8, Metascape, STRING, TIMER, the Kaplan-Meier plotter, The Human Protein Atlas, MirTarBase, and cBioportal.

The transcriptional levels of PEX6/7/10/11B/13/16 in BC tissues were significantly elevated, whereas the transcriptional levels of PEX2/3/5/11A/12/19 were significantly reduced. High expression levels of PEX 2/3/10/12/11G /26/13/16/14 were significantly related to shorter relapse-free survival, and higher mRNA expression of PEX 11B/11G/11A/12/19 was significantly associated with longer overall survival of BC patients. We identified has-miR-4318 and has-7106-3p as more correlated miRNAs with the PEX family.

Our results may provide novel insights for the selection of therapeutic targets and prognostic biomarkers for BC.